Evergraf 0.5mg tablet - Everolimus | Apple Pharmaceuticals

Description

Evergraf 0.5mg consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.
Evergraf 0.5mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

Primarily Evergraf 0.5mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism Of Action

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage

Evergraf 0.5mg tablets should be given with or without food.
The dosage regimen of Evergraf 0.5mg;
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Precautions

Lymphomas:
The developed hazard of skin cancers, the patient may protect from UV light

Serious infections :
Patients getting Evergraf 0.5mg have a severe risk of achieving various infections related to bacteria, virus, and fungi.

Hepatic artery thrombosis :
Evergraf 0.5mg therapy should not be recommended in liver transplant patients,

Nephrotoxicity :
While using Evergraf 0.5mg in renal impaired patients Renal function should be monitored frequently; drug use with caution.

Drug Interaction

Evergraf 0.5mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Evergraf 0.5mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Evergraf 0.5mg with cyclosporine will increase the AUC level of Everolimus frequently.
Combination ketoconazole with Evergraf 0.5mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy

Pregnancy category of Everolimus C
In patients, Evergraf 0.5mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

Lactation

Breastfeeding should not be suggested

Storage

Evergraf 0.5mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with a medical practitioner and follow the instructions given by them.
Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evergraf-0.5mg.php